



[Print](#) | [Close this window](#)

BioTime To Present At 2009 World Stem Cell Summit

9/21/2009 7:19 AM ET

Shares of BioTime Inc. (BTIM.OB), which trade over the counter, have been on a steady rise -- appreciating over 150%, since the beginning of this year. The biotechnology company is focused on regenerative medicine and blood plasma volume expanders.

BioTime's lead product, Hextend, is a blood plasma expander manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ CheilJedang Corp. under exclusive licensing agreements. Plasma volume expanders are solutions used to replace blood volume lost during surgery.

Regenerative medicine is a novel way of treating degenerative diseases by using specially-grown tissues and cells (including stem cells), laboratory-made compounds, and artificial organs.

At the 2009 World Stem Cell Summit meeting in Baltimore, Maryland, BioTime will make a presentation on September 23, addressing the challenges the regenerative medicine industry is currently facing due to cellular contamination producing undesired cell and tissues at the site of engraftment and the potential benefits of the company's purification technology.

The company is slated to describe the progress in its ACTCellerate technology platform. BioTime acquired license to use ACTCellerate technology from Advanced Cell Technology Inc. (ACTC.PK) last July.

According to BioTime, ACTCellerate allows the rapid isolation of novel highly purified embryonic progenitor cells. Embryonic progenitors are cells intermediate between embryonic stem cells and fully differentiated cells. The progenitor cells are relatively easy to manufacture on a large scale and in a purified state, which may make it advantageous to work with these cells compared to the direct use of embryonic stem cells.

Late April, the California Institute for Regenerative Medicine approved a grant to BioTime of \$4.7 million to fund research related

to its ACTCellerate embryonic stem cell technology.

Regenerative medicine, a multi-billion dollar opportunity, is gaining considerable attention. The company is optimistic that ACTCellerate technology reduces the chances of inappropriate cells or tissues forming at the site of a therapeutic tissue or cell graft, a concern currently facing the regenerative industry. Will the ACTCellerate technology prove to be a breakthrough technology in hastening the translation of human embryonic stem cell-based therapies into safe and effective products for routine clinical practice? Stay tuned...

BTIM.OB, which has thus far hit a 52-week low of \$0.70 and 52-week high of \$4.60, closed Friday's trading at \$4.50.

Copyright © 2009 RTTNews.com, Inc. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without prior written consent of RTTNews.